Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer.
暂无分享,去创建一个
T. Ragg | C. Klein | G. Schlimok | D. Weckermann | R. Harzmann | S. Bertz | H. Arnholdt | B. Polzer | A. Blana | Thomas Ragg
[1] B. Trask,et al. Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. , 2008, Cancer research.
[2] R. Weinberg,et al. Systemic Endocrine Instigation of Indolent Tumor Growth Requires Osteopontin , 2008, Cell.
[3] A. Ullrich,et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. , 2008, Cancer cell.
[4] R. Eils,et al. Systemic spread is an early step in breast cancer. , 2008, Cancer cell.
[5] N. Kawata,et al. Prostate‐specific antigen failure within 2 years of radical prostatectomy predicts overall survival , 2006, International journal of urology : official journal of the Japanese Urological Association.
[6] S. Rafii,et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.
[7] P. Walsh,et al. Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.
[8] T. Fehm,et al. A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.
[9] S. Braun,et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence , 2005, Cancer.
[10] R. Demicheli,et al. Does surgery unfavourably perturb the "natural history" of early breast cancer by accelerating the appearance of distant metastases? , 2005, European journal of cancer.
[11] R. Demicheli,et al. Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients , 2004, Breast Cancer Research.
[12] N. Stoecklein,et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer , 2002, The Lancet.
[13] Michael Baudis,et al. Progenetix.net: an online repository for molecular cytogenetic aberration data , 2001, Bioinform..
[14] D. Wood,et al. Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer , 2001, The Prostate.
[15] G. Schlimok,et al. Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. , 2001, The Journal of urology.
[16] T. Dimpfl,et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.
[17] R. Cote,et al. Detection and clinical importance of micrometastatic disease. , 1999, Journal of the National Cancer Institute.
[18] T. Imazawa,et al. Serum concentrations of hepatocyte growth factor in breast cancer patients. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] N Gunduz,et al. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. , 1989, Cancer research.
[20] C. Klein. The systemic progression of human cancer: a focus on the individual disseminated cancer cell--the unit of selection. , 2003, Advances in cancer research.